{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:14:48Z","timestamp":1781190888912,"version":"3.54.1"},"reference-count":30,"publisher":"The Pediatric Pharmacy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec id=\"st1\">\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Baclofen is used for hypertonia in infants despite limited dosing guidance. This study describes enteral baclofen prescribing in patients 12 months of age and younger.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st2\">\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This single-center, retrospective review evaluated infants receiving enteral baclofen from January 2013 to December 2022. Regimen information, including dose, frequency, age, weight, and duration of treatment for up to 1 year following initiation, was assessed. Other outcomes included place in therapy, safety, and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st3\">\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>This study included 108 patients with 423 total regimens. At initiation, the median baclofen dose was 1.3 mg, corresponding to a weight-based dose (WBD) of 0.2 mg\/kg, a total daily dose (TDD) of 3 mg, and a weight-based total daily dose (wTDD) of 0.5 mg\/kg\/day. Sixty-one patients (56.5%) received baclofen 3 times daily at initiation. The patients\u2019 longest-tolerated regimen had a median dose of 2.8 mg, corresponding to a WBD of 0.4 mg\/kg, a TDD of 9 mg, and a wTDD of 1.3 mg\/kg\/day. Hypoxemic-ischemic encephalopathy and brain injury were the most common etiologies of hypertonia. Baclofen was the first antispastic agent for 37 patients (34.3%). Twenty-four patients (22.2%) discontinued baclofen within 1 year. Four patients (3.7%) stopped baclofen due to adverse effects (sedation and emesis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st4\">\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The median initiation dose of baclofen in infants was lower than the recommended dose for patients aged younger than 2 years, highlighting variability in practice. The baclofen regimens used in this study were safe and well-tolerated. These findings provide insight into baclofen prescribing for infants with hypertonia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5863\/jppt-25-00052","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:35:13Z","timestamp":1776472513000},"page":"372-379","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Enteral Baclofen Prescribing Practices for Infants With Hypertonia"],"prefix":"10.5863","volume":"31","author":[{"given":"Hope E.","family":"DiTaranto","sequence":"first","affiliation":[{"name":"Department of Pharmacy (HED, AM, RK, JZ), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrela","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (HED, AM, RK, JZ), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kendsersky","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (HED, AM, RK, JZ), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zook","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (HED, AM, RK, JZ), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Katz","sequence":"additional","affiliation":[{"name":"Division of Physical Medicine and Rehabilitation (EK, SHE, JMK), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Evans","sequence":"additional","affiliation":[{"name":"Division of Physical Medicine and Rehabilitation (EK, SHE, JMK), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"King","sequence":"additional","affiliation":[{"name":"Division of Physical Medicine and Rehabilitation (EK, SHE, JMK), Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"key":"JPPT-25-00052-b01","series-title":"Baclofen","author":"Ghanavatian","year":"2025","unstructured":"Ghanavatian S, Derian A. Baclofen. Treasure Island, FL: StatPearls Publishing; 2025."},{"key":"JPPT-25-00052-b02","series-title":"Spasticity in Under 19s: Management","year":"2016","unstructured":"Spasticity in Under 19s: Management. London, UK: National Institute for Health and Care Excellence; 2016."},{"key":"JPPT-25-00052-b03","series-title":"SAGE Open Med","article-title":"Baclofen therapeutics, toxicity, and withdrawal: a narrative review","volume":"9","author":"Romito","year":"2021","unstructured":"Romito JW, Turner ER, Rosener JA, et al. Baclofen therapeutics, toxicity, and withdrawal: a narrative review. SAGE Open Med. 2021;9."},{"issue":"1","key":"JPPT-25-00052-b04","series-title":"Br J Pharmacol","first-page":"29","article-title":"Actions of the GABAB agonist, (\u2212)-baclofen, on neurones in deep dorsal horn of the rat spinal cord in vitro","volume":"96","author":"Allerton","year":"1989","unstructured":"Allerton CA, Boden PR, Hill RG. Actions of the GABAB agonist, (\u2212)-baclofen, on neurones in deep dorsal horn of the rat spinal cord in vitro. Br J Pharmacol. 1989;96(1):29\u201338."},{"issue":"5","key":"JPPT-25-00052-b05","series-title":"J Pediatr","first-page":"1181","article-title":"Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy","volume":"164","author":"He","year":"2014","unstructured":"He Y, Brunstrom-Hernandez JE, Thio LL, et al. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. J Pediatr. 2014;164(5):1181\u20131188.e8."},{"issue":"2","key":"JPPT-25-00052-b06","series-title":"Clin Transl Sci","first-page":"e70171","article-title":"National prescribing practices for pediatric dystonia among providers in the United States","volume":"18","author":"Davis","year":"2025","unstructured":"Davis SPW, Kane N, Botteron HE, Gelineau-Morel R. National prescribing practices for pediatric dystonia among providers in the United States. Clin Transl Sci. 2025;18(2):e70171."},{"key":"JPPT-25-00052-b07","article-title":"Lexi-Drugs. Lexicomp","year":"2022","unstructured":"Average Weights and Surface Areas. Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. Updated August 4, 2022. Accessed September 3, 2025. http:\/\/online.lexi.com"},{"issue":"12","key":"JPPT-25-00052-b08","series-title":"J Child Neurol","first-page":"1090","article-title":"Oral baclofen and clonidine for treatment of spasticity in children","volume":"21","author":"Lubsch","year":"2006","unstructured":"Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. J Child Neurol. 2006;21(12):1090\u20131092."},{"issue":"2","key":"JPPT-25-00052-b09","series-title":"J Child Neurol","first-page":"197","article-title":"Is oral baclofen effective in neonatal hypertonia?","volume":"27","author":"Schulz","year":"2012","unstructured":"Schulz E, Mathew OP. Is oral baclofen effective in neonatal hypertonia? J Child Neurol. 2012;27(2):197\u2013199."},{"issue":"6","key":"JPPT-25-00052-b10","series-title":"J Pediatr Pharmacol Ther","first-page":"424","article-title":"Glomerular filtration rate estimation formulas for pediatric and neonatal use","volume":"23","author":"Muhari-Stark","year":"2018","unstructured":"Muhari-Stark E, Burckart GJ. Glomerular filtration rate estimation formulas for pediatric and neonatal use. J Pediatr Pharmacol Ther. 2018;23(6):424\u2013431."},{"issue":"2","key":"JPPT-25-00052-b11","series-title":"J Pediatr Pharmacol Ther","first-page":"159","article-title":"Evaluating gabapentin dosing, efficacy and safety in infants","volume":"29","author":"Fleser","year":"2024","unstructured":"Fleser L, Tibbetts E, Hanson A, et al. Evaluating gabapentin dosing, efficacy and safety in infants. J Pediatr Pharmacol Ther. 2024;29(2):159\u2013168."},{"issue":"2","key":"JPPT-25-00052-b12","series-title":"Eur J Clin Pharmacol","first-page":"181","article-title":"Plasma and urinary excretion kinetics of oral baclofen in healthy subjects","volume":"37","author":"Wuis","year":"1989","unstructured":"Wuis EW, Dirks MJ, Termond EF, Vree TB, Van der Kleijn E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol. 1989;37(2):181\u2013184."},{"key":"JPPT-25-00052-b13","series-title":"Front Med (Lausanne)","first-page":"1363097","article-title":"Impact of preterm birth on kidney health and development","volume":"11","author":"Deffrennes","year":"2024","unstructured":"Deffrennes S, Rayyan M, Fidlers T, van den Heuvel L, Levtchenko E, Arcolino FO. Impact of preterm birth on kidney health and development. Front Med (Lausanne). 2024;11:1363097."},{"issue":"2","key":"JPPT-25-00052-b14","series-title":"Phys Ther","first-page":"206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","unstructured":"Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206\u2013207."},{"issue":"5","key":"JPPT-25-00052-b15","series-title":"Dev Med Child Neurol","first-page":"e83","article-title":"Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children","volume":"52","author":"Jethwa","year":"2010","unstructured":"Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D. Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. Dev Med Child Neurol. 2010;52(5):e83\u2013e87."},{"key":"JPPT-25-00052-b01","series-title":"Baclofen","author":"Ghanavatian","year":"2025","unstructured":"Ghanavatian S, Derian A. Baclofen. Treasure Island, FL: StatPearls Publishing; 2025."},{"key":"JPPT-25-00052-b02","series-title":"Spasticity in Under 19s: Management","year":"2016","unstructured":"Spasticity in Under 19s: Management. London, UK: National Institute for Health and Care Excellence; 2016."},{"key":"JPPT-25-00052-b03","series-title":"SAGE Open Med","article-title":"Baclofen therapeutics, toxicity, and withdrawal: a narrative review","volume":"9","author":"Romito","year":"2021","unstructured":"Romito JW, Turner ER, Rosener JA, et al. Baclofen therapeutics, toxicity, and withdrawal: a narrative review. SAGE Open Med. 2021;9."},{"issue":"1","key":"JPPT-25-00052-b04","series-title":"Br J Pharmacol","first-page":"29","article-title":"Actions of the GABAB agonist, (\u2212)-baclofen, on neurones in deep dorsal horn of the rat spinal cord in vitro","volume":"96","author":"Allerton","year":"1989","unstructured":"Allerton CA, Boden PR, Hill RG. Actions of the GABAB agonist, (\u2212)-baclofen, on neurones in deep dorsal horn of the rat spinal cord in vitro. Br J Pharmacol. 1989;96(1):29\u201338."},{"issue":"5","key":"JPPT-25-00052-b05","series-title":"J Pediatr","first-page":"1181","article-title":"Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy","volume":"164","author":"He","year":"2014","unstructured":"He Y, Brunstrom-Hernandez JE, Thio LL, et al. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. J Pediatr. 2014;164(5):1181\u20131188.e8."},{"issue":"2","key":"JPPT-25-00052-b06","series-title":"Clin Transl Sci","first-page":"e70171","article-title":"National prescribing practices for pediatric dystonia among providers in the United States","volume":"18","author":"Davis","year":"2025","unstructured":"Davis SPW, Kane N, Botteron HE, Gelineau-Morel R. National prescribing practices for pediatric dystonia among providers in the United States. Clin Transl Sci. 2025;18(2):e70171."},{"key":"JPPT-25-00052-b07","article-title":"Lexi-Drugs. Lexicomp","year":"2022","unstructured":"Average Weights and Surface Areas. Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. Updated August 4, 2022. Accessed September 3, 2025. http:\/\/online.lexi.com"},{"issue":"12","key":"JPPT-25-00052-b08","series-title":"J Child Neurol","first-page":"1090","article-title":"Oral baclofen and clonidine for treatment of spasticity in children","volume":"21","author":"Lubsch","year":"2006","unstructured":"Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. J Child Neurol. 2006;21(12):1090\u20131092."},{"issue":"2","key":"JPPT-25-00052-b09","series-title":"J Child Neurol","first-page":"197","article-title":"Is oral baclofen effective in neonatal hypertonia?","volume":"27","author":"Schulz","year":"2012","unstructured":"Schulz E, Mathew OP. Is oral baclofen effective in neonatal hypertonia? J Child Neurol. 2012;27(2):197\u2013199."},{"issue":"6","key":"JPPT-25-00052-b10","series-title":"J Pediatr Pharmacol Ther","first-page":"424","article-title":"Glomerular filtration rate estimation formulas for pediatric and neonatal use","volume":"23","author":"Muhari-Stark","year":"2018","unstructured":"Muhari-Stark E, Burckart GJ. Glomerular filtration rate estimation formulas for pediatric and neonatal use. J Pediatr Pharmacol Ther. 2018;23(6):424\u2013431."},{"issue":"2","key":"JPPT-25-00052-b11","series-title":"J Pediatr Pharmacol Ther","first-page":"159","article-title":"Evaluating gabapentin dosing, efficacy and safety in infants","volume":"29","author":"Fleser","year":"2024","unstructured":"Fleser L, Tibbetts E, Hanson A, et al. Evaluating gabapentin dosing, efficacy and safety in infants. J Pediatr Pharmacol Ther. 2024;29(2):159\u2013168."},{"issue":"2","key":"JPPT-25-00052-b12","series-title":"Eur J Clin Pharmacol","first-page":"181","article-title":"Plasma and urinary excretion kinetics of oral baclofen in healthy subjects","volume":"37","author":"Wuis","year":"1989","unstructured":"Wuis EW, Dirks MJ, Termond EF, Vree TB, Van der Kleijn E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol. 1989;37(2):181\u2013184."},{"key":"JPPT-25-00052-b13","series-title":"Front Med (Lausanne)","first-page":"1363097","article-title":"Impact of preterm birth on kidney health and development","volume":"11","author":"Deffrennes","year":"2024","unstructured":"Deffrennes S, Rayyan M, Fidlers T, van den Heuvel L, Levtchenko E, Arcolino FO. Impact of preterm birth on kidney health and development. Front Med (Lausanne). 2024;11:1363097."},{"issue":"2","key":"JPPT-25-00052-b14","series-title":"Phys Ther","first-page":"206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","unstructured":"Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206\u2013207."},{"issue":"5","key":"JPPT-25-00052-b15","series-title":"Dev Med Child Neurol","first-page":"e83","article-title":"Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children","volume":"52","author":"Jethwa","year":"2010","unstructured":"Jethwa A, Mink J, Macarthur C, Knights S, Fehlings T, Fehlings D. Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. Dev Med Child Neurol. 2010;52(5):e83\u2013e87."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/3\/article-p372.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/3\/article-p372.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/3\/article-p372.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:47:02Z","timestamp":1781189222000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/3\/article-p372.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5863\/jppt-25-00052","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}